PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22633931-0 2012 Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors. vandetanib 60-70 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 151-156 22633931-0 2012 Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors. vandetanib 60-70 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 157-162 22633931-1 2012 The objectives of this study were (i) to characterize the interaction of vandetanib with P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp1) in vitro and in vivo (ii) to study the modulation of P-gp and BCRP mediated efflux of vandetanib with specific transport inhibitors and m-TOR inhibitors, everolimus and temsirolimus. vandetanib 73-83 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 149-154 22633931-1 2012 The objectives of this study were (i) to characterize the interaction of vandetanib with P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp1) in vitro and in vivo (ii) to study the modulation of P-gp and BCRP mediated efflux of vandetanib with specific transport inhibitors and m-TOR inhibitors, everolimus and temsirolimus. vandetanib 73-83 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 218-222 22633931-1 2012 The objectives of this study were (i) to characterize the interaction of vandetanib with P-glycoprotein (P-gp) and breast cancer resistance protein (Bcrp1) in vitro and in vivo (ii) to study the modulation of P-gp and BCRP mediated efflux of vandetanib with specific transport inhibitors and m-TOR inhibitors, everolimus and temsirolimus. vandetanib 242-252 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 149-154 22633931-4 2012 In vitro studies suggested that vandetanib is a high affinity substrate of Bcrp1 but is not transported by P-gp. vandetanib 32-42 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 75-80 22633931-5 2012 Interestingly, in vivo brain distribution studies in FVB wild type mice indicated that vandetanib penetration into the brain is restricted by both Bcrp1 and P-gp mediated active efflux at the blood brain barrier (BBB). vandetanib 87-97 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 147-152 22633931-6 2012 Co-administration of elacridar, a dual P-gp/BCRP inhibitor increased the brain to plasma concentration ratio of vandetanib upto 5 fold. vandetanib 112-122 ATP binding cassette subfamily G member 2 (Junior blood group) Mus musculus 44-48